Guardant Health Earnings: Analysts Expect Another Loss, But Revenue Growth Tells a Different Story

Guardant Health reports second-quarter 2026 earnings after the close on July 30, with analysts expecting a loss of $0.74 per share on revenue of $314.2 million. The central question is whether the oncology testing company can sustain its recent revenue momentum while narrowing losses—a critical test for a growth story that has delivered mixed earnings surprises over the past year. With the stock trading well above its 200-day moving average but below recent highs, investors will be watching for signs that the path to profitability is accelerating.

Part 1: Earnings Preview

Guardant Health is a precision oncology company that develops blood-based tests for cancer detection and monitoring, serving both screening and treatment selection markets. The company's liquid biopsy platform has positioned it as a leader in the emerging field of early cancer detection, making its financial trajectory closely watched by both healthcare and growth investors.

Guardant Health reports Q2 2026 earnings after the close on July 30, with the consensus calling for a loss of $0.74 per share on revenue of $314.2 million—representing 35% revenue growth year-over-year. The company most recently reported Q1 2026 results with a loss of $0.85 per share, missing estimates by nearly 20%. Compared to the same quarter last year (Q2 2025), when GH posted a loss of $0.79 per share, the current estimate implies a 6.3% improvement in the bottom line.

Three key themes define this earnings story. Revenue acceleration remains the primary focus—analysts expect the company to sustain its strong top-line growth trajectory, with revenue estimates up more than a third year-over-year as adoption of its Guardant360 and Shield screening tests expands. Path to profitability is equally critical, as investors want evidence that operating leverage is improving and losses are narrowing on schedule; the company is expected to reduce its full-year 2026 loss to $2.89 per share from $3.32 in 2025. Finally, commercial execution and reimbursement progress will be scrutinized—any updates on payer coverage, Medicare decisions, or physician adoption rates could significantly move the stock.

Heading into the release, Wall Street remains overwhelmingly bullish. Royal Bank of Canada recently initiated coverage with an "outperform" rating and a $185 price target, while Evercore set a $200 target, citing confidence in the company's long-term growth potential. Canaccord Genuity raised its target to $205, reflecting optimism about the commercial ramp. However, some caution persists—Piper Sandler's more conservative $127 target suggests not all analysts are convinced the valuation is justified at current levels.

Part 2: Historical Earnings Performance

Guardant Health's recent earnings history reveals an inconsistent pattern of surprises. Over the past four quarters, the company has delivered two beats and two significant misses. In Q2 2025, GH met estimates exactly with a loss of $0.79 per share. The following quarter (Q3 2025) brought a modest beat, with a reported loss of $0.74 versus the $0.80 estimate—a 7.5% positive surprise. However, Q4 2025 marked a sharp disappointment, with the company posting a loss of $1.00 against expectations of $0.81, missing by 23.5%. Most recently, Q1 2026 saw another miss, with a loss of $0.85 compared to the $0.71 consensus—a 19.7% negative surprise.

The trend suggests volatility rather than consistency. While the company has demonstrated the ability to beat estimates when execution is strong, the two recent consecutive misses raise questions about whether near-term profitability improvements are on track. The magnitude of the Q4 2025 and Q1 2026 misses—both exceeding estimates by double-digit percentages—indicates that forecasting GH's quarterly performance remains challenging. Investors should approach this release with caution, as the company's track record over the past year does not inspire confidence in its ability to meet the $0.74 consensus estimate.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Guardant Health typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 3.77% and Day +1 move of 10.12%. The Day +1 reaction has been particularly dramatic, with intraday ranges averaging 13.18%—indicating that GH stock can swing violently in the session following results. The most extreme example came after the October 2025 report, when the stock surged 27.87% on Day +1 following a positive earnings surprise. Conversely, negative surprises have triggered sharp selloffs, such as the 9.56% decline after the February 2025 miss. The pattern is clear: when GH beats, the stock can rally aggressively; when it misses, the downside can be swift and substantial. Given the two consecutive misses heading into this release, investors should be prepared for heightened volatility, particularly if the company fails to meet expectations again.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 13.26% through the August 21 expiration, which aligns closely with the stock's historical Day +1 average range of 13.18%. This suggests options traders are anticipating typical post-earnings volatility rather than an outsized reaction, though the wide range reflects the binary nature of GH's earnings outcomes.

Part 3: What Analysts Are Saying

Wall Street maintains a strongly bullish stance on Guardant Health, with the consensus rating at 4.84 out of 5.0—firmly in "Strong Buy" territory. The analyst community includes 22 Strong Buy ratings, 2 Moderate Buys, and just 1 Hold, with no sell ratings. This overwhelmingly positive sentiment has remained unchanged over the past month, indicating stable conviction despite the stock's recent earnings misses.

The average price target of $174.61 implies 21% upside from the current price of $144.16, with the range of estimates spanning from a low of $125 to a high of $215. The wide target range reflects differing views on the company's near-term execution risk versus its long-term growth potential. The most bullish analysts see the company's leadership in liquid biopsy and early cancer detection as justifying a significant premium, while more conservative voices point to profitability concerns and execution challenges as reasons for caution. Despite recent earnings disappointments, the analyst community's conviction has not wavered—suggesting that most on the Street view any near-term volatility as a buying opportunity in a compelling long-term growth story.

Part 4: Technical Picture

Guardant Health's technical setup heading into earnings shows a mixed picture, with the stock consolidating below recent highs but maintaining support above key longer-term moving averages. The Barchart Technical Opinion currently stands at 80% Buy, unchanged from last week but down from 100% Buy a month ago, reflecting some loss of momentum as the stock has pulled back from its highs.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled, with the stock digesting recent gains
• Medium-term (100% Buy): Strong buy signal indicates the intermediate-term trend remains firmly positive despite the recent pullback
• Long-term (100% Buy): Strong buy signal confirms the broader uptrend is intact, supported by the stock's position well above its 200-day moving average

Trend Characteristics: The combination of Strong strength and Average direction suggests the stock is in a well-established uptrend but currently experiencing normal consolidation rather than aggressive momentum.

The stock is trading at $144.16, positioned below its 5-day ($146.16), 10-day ($149.28), and 20-day ($156.25) moving averages, indicating short-term weakness. However, it remains above its 50-day ($139.70), 100-day ($114.42), and 200-day ($106.37) moving averages, confirming the longer-term uptrend is intact.

The technical setup is cautiously supportive but not ideal for earnings. While the stock's position above all major long-term moving averages provides a cushion, the recent pullback from the $156 level and failure to hold short-term moving averages suggests momentum has stalled. The 20-day moving average at $156.25 now represents immediate resistance, while the 50-day at $139.70 serves as nearby support. Given the stock's tendency for large post-earnings moves and its current position in a short-term downtrend within a longer-term uptrend, the technical picture suggests vulnerability to further downside if the company disappoints, but also potential for a sharp reversal higher if results exceed expectations.